Montréal, QC, Canada (Jan 31, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it will be participating at the following investor conferences:
Evercore ISI’s 2024 Emerging Private Biotech Conference
- Date: February 28 – 29th, 2024
- Time of presentation: Wednesday February 28th, 9 – 9:30AM
- Location: Virtual
Leerink Partners Global Biopharma Conference 2024
- Date: March 11 – 13th, 2024
- Location: Miami, FL
About 35Pharma
35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment of Pulmonary Hypertension, Heart Failure and obesity. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta ligands while sparing beneficial homeostatic ligands.
Contact
Julia Schoelermann, VP Corporate Development, 35Pharma
info@35pharma.com
For more information, please visit www.35pharma.com
